Puma Biotechnology
PBYI
149 hedge funds and large institutions have $2.01B invested in Puma Biotechnology in 2016 Q3 according to their latest regulatory filings, with 55 funds opening new positions, 37 increasing their positions, 41 reducing their positions, and 16 closing their positions.
244% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 16
112% more capital invested
Capital invested by funds: $948M → $2.01B (+$1.06B)
35% more funds holding
Funds holding: 110 → 149 (+39)
14% more call options, than puts
Call options by funds: $36.2M | Put options by funds: $31.8M
10% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 41
5.56% less ownership
Funds ownership: 97.9% → 92.34% (-5.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$34.9M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$33.5M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$33M |
| 4 |
Millennium Management
New York
|
+$28.1M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$43.8M |
| 2 |
O
OrbiMed
New York
|
-$29.4M |
| 3 |
CCM
Cornerstone Capital Management
Edina,
Minnesota
|
-$23.1M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
-$20.2M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$19.6M |
PBYI Hedge Fund Activity: Q3 2016 in Review
149 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q3 2016, worth a combined $2.01B — up 112% from $948M a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new PBYI positions and 16 closed out — a net gain of 39 holders — while 37 added to existing stakes and 41 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $34.9M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $43.8M sold.
- 149 institutional investors held Puma Biotechnology (PBYI) as of Q3 2016, up from 110 in Q2 2016.
- Funds reported $2.01B of Puma Biotechnology stock for Q3 2016, up 112% quarter-over-quarter.
- 55 funds opened new Puma Biotechnology positions in Q3 2016 and 16 closed out, a net change of +39 holders.
- The largest Puma Biotechnology buyer in Q3 2016 was Wellington Management Group, an estimated $34.9M added.
- The largest Puma Biotechnology seller in Q3 2016 was PFM Health Sciences, an estimated $43.8M sold.
Based on aggregated 13F filings for Q3 2016.